Search results
Added:
1 week ago
Source:
Radcliffe Vascular
The optimal management for asymptomatic carotid stenosis has been a subject of debate, particularly with advancements in medical therapy. New findings from the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) provide clarity, suggesting a benefit for carotid-artery stenting when added to intensive medical management.¹MethodologyCREST-2 involved…
View more
Added:
3 weeks ago
Source:
Radcliffe Cardiology
The long-term benefits of revascularization over medical therapy for patients with stable coronary artery disease (CAD) remain a subject of clinical debate. New long-term follow-up data from the Fractional Flow Reserve versus Angiography for Multivessel Evaluation 2 (FAME 2) trial provide further insight, demonstrating a sustained benefit for percutaneous coronary intervention (PCI) guided by…
View more
Added:
3 weeks ago
Source:
Radcliffe Vascular
The optimal management for patients with high-grade asymptomatic carotid stenosis remains a key clinical question, particularly with advancements in medical therapy and revascularisation techniques. The CREST-2 trials were designed to assess whether adding revascularisation to intensive medical management provides a greater benefit than intensive medical management alone in this patient…
View more
Added:
5 months ago
Source:
Transcatheter Academy
The long-term durability of complete revascularization in older patients with myocardial infarction (MI) and multivessel disease has been a subject of recent debate. New 3-year follow-up data from the Functional Assessment in Elderly MI Patients With Multivessel Disease (FIRE) trial show that the clinical benefits of a physiology-guided complete revascularization strategy are sustained over time…
View more
Added:
5 months ago
Source:
Transcatheter Academy
The use of paclitaxel-coated devices did not reduce the rate of major amputations or death in patients with chronic limb-threatening ischaemia (CLTI) undergoing infrainguinal endovascular revascularisation, according to the results of a large registry-based trial.¹ While drug-coated devices are commonly used in peripheral interventions, their effect on amputation risk has been uncertain.²The…
View more
Author(s):
Brian Lindman
Added:
10 months ago
ACC 2025 - Primary findings from EARLY-TAVR show the benefit of early TAVR intervention was consistent across biomarker subgroups.Dr Brian Lindman (Vanderbilt University Medical Center, Nashville, US) joins us onsite at ACC 2025 to discuss findings from the primary biomarker analysis from the EARLY TAVR trial (NCT03042104; Edwards Lifesciences). The analysis investigated cardiac biomarkers in…
View more
Exploring the Potential of Sensor-Guided TAVI
Video Series
Author(s):
Jonathan Schwartz
Added:
2 months ago
PCR London Valves 2025 - In this interview, Dr Jonathan Schwartz, leading structural interventional cardiologist at the Sanger Heart and Vascular Institute, Lake Forest University (Charlotte, NC, US) shares his insights into the evolving landscape of transcatheter tricuspid valve therapies.Dr Schwartz examines the latest real-world and clinical trial evidence for the EVOQUE and TriClip systems,…
View more
Author(s):
Roberto Garbo
,
,
,
et al
Added:
1 year ago
In this on-demand version of the live broadcast, chaired by Dr Tomáš Kovárník (Charles University, Prague, CZ), faculty showcase the latest advancements in CTO PCI procedures with state-of-the-art technology.Investigate the possibility of shortening stent lengths with precision physiology guidance, featuring Dr Mohamed Ayoub's (University Heart Center NRW, Bad Oeynhausen, DE) presentationExplore…
View more
Author(s):
Added:
7 months ago
New York Valves 25 - A substudy of TRISCEND II investigating the effect of transcatheter tricuspid valve replacement (TTVR) on preference-weighted health status showed significant benefits in patients who received TTVR.We are joined by Dr Suzanne Arnold (Saint Luke's Mid America Heart Institute, US) to discuss the findings from a substudy of the TRISCEND II trial, which aimed to create an…
View more